Polaris Group Initiates P-IIa Clinical Study for NASH, Dosing First Patient with ADI-PEG 20
Shots:
- Polaris announces the successful dosing of the first patient in the P-IIa clinical study for Non-Alcoholic Steatohepatitis (NASH), a progressive liver disease linked to obesity and metabolic syndrome
- The Phase IIa study, a randomized, double-blind, placebo-controlled trial, aims to evaluate ADI-PEG 20 impact on liver fat content, histology, and other endpoints crucial for NASH patients (n=60)
- ADI-PEG 20, (pegylated arginine deiminase, pegargiminase) is an investigational drug, that targets key pathways in NASH pathogenesis
Ref: Globenewswire | Image: Polaris
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
